Camurati-Engelmann disease is a rare genetic bone disorder that causes painful, dense bones, most often in the legs and arms. Many people with Camurati-Engelmann disease first notice deep, tiring bone pain, muscle weakness, and fatigue that can limit walking or daily tasks. It usually begins in childhood or the teen years and tends to be lifelong, with symptoms that can flare and ease over time. Serious complications are uncommon, but some may develop nerve compression, limb deformity, or hearing and vision issues, so regular follow-up helps. Treatment focuses on managing pain and inflammation with medicines like NSAIDs or corticosteroids, physical therapy to maintain strength and mobility, and monitoring by specialists.
Overview
Camurati-engelmann diseaseSymptoms
Camurati-Engelmann disease often causes deep bone pain in legs and arms, muscle weakness, and easy fatigue. Many develop a waddling walk, limb tenderness; some have headaches or slow growth. Early symptoms of Camurati-Engelmann disease usually appear in childhood.
Outlook and prognosis
Most people with Camurati-Engelmann disease live a normal lifespan. Symptoms often fluctuate, and many improve after growth finishes; targeted care can ease pain, support mobility, and protect bone and muscle health. Regular follow-up helps manage flares and prevent complications.
Causes and risk factors
Camurati-Engelmann disease results from TGFB1 gene mutations, typically autosomal dominant; many arise de novo. The key risk is an affected parent or family history. Age, hormones, intercurrent illness, and physical stress may modify symptom severity.
Genetic influences
Genetics are central in Camurati-Engelmann disease, which is usually caused by inherited changes in the TGFB1 gene. Most cases follow an autosomal dominant pattern, though new (de novo) variants can occur. Genetic testing confirms the diagnosis and enables family counseling.
Diagnosis
Doctors suspect Camurati‑Engelmann disease from clinical features such as long‑bone pain, muscle weakness, and a waddling gait. X‑rays showing symmetric diaphyseal bone thickening support the diagnosis. Genetic tests for TGFB1 variants confirm the genetic diagnosis of Camurati‑Engelmann disease.
Treatment and drugs
Treatment for Camurati-Engelmann disease focuses on easing bone pain, improving mobility, and protecting muscle strength. Doctors often use corticosteroids or losartan, tailored physical therapy, and careful vitamin D and calcium balance; surgery is uncommon but considered for nerve or pressure problems. Regular follow-up helps adjust medicines and activity as symptoms change.
Symptoms
Many living with Camurati-Engelmann disease notice deep, aching bone pain and muscle tiredness that can limit walking, running, or standing for long. Early features of Camurati-Engelmann disease often show up in childhood or the teen years as leg pain, fatigue, and a side-to-side, waddling walk. You might notice small changes at first—like getting winded on short walks or needing more breaks—before the pattern becomes clearer. When the skull is involved, headaches, pressure behind the eyes, or changes in hearing or vision can occur.
Aching deep in the legs or arms can flare with activity or at night. It may feel tender to press and make it hard to stand or walk for long. Bone pain is a hallmark of Camurati-Engelmann disease.
Legs can feel heavy, and stairs or rising from a chair take extra effort. Muscles may look smaller over time.
A side-to-side walking pattern may appear, often with a wider stance. Balance can feel off, and running or jumping is harder.
Even short walks or light chores can lead to outsized tiredness. Many need frequent breaks to get through school, work, or play.
How people usually first notice Camurati-engelmann disease?
Families often notice the first signs of Camurati‑Engelmann disease in childhood as aching, heavy-feeling legs, fatigue after short walks, and a waddling or toe‑walking gait, even though routine exams may look normal. Doctors are usually alerted by persistent limb pain, muscle weakness, and delayed motor milestones, followed by X‑rays showing thickened shafts of the long bones, which confirm how Camurati‑Engelmann disease is first noticed. In some cases, prenatal or early clues are absent and the condition is first recognized later in adolescence when exercise intolerance, shin pain, and a characteristic narrow marrow cavity on imaging prompt evaluation.
Types of Camurati-engelmann disease
Camurati-Engelmann disease is a rare genetic bone disorder with a few recognized clinical variants rather than separate diseases. These variants reflect which bones are most affected, when symptoms start, and how severe the bone thickening becomes over time. People may notice different sets of symptoms depending on their situation. When reading about types of Camurati-Engelmann disease, you’ll often see mentions of classic, milder, or segmental forms rather than different genetic causes.
Classic diffuse form
Symptoms usually begin in childhood or adolescence with deep bone pain and fatigue. Bone thickening tends to be widespread in the long bones and can progress to the skull in some. Early symptoms of Camurati-Engelmann disease in this form can include leg pain with walking and a waddling gait.
Adult-onset milder
Signs often appear later, sometimes in the 20s to 40s, with intermittent limb pain and less obvious bone changes on imaging. People with this form may have fewer activity limits and slower progression. Not everyone will experience every type.
Segmental/monomelic
Only one limb or a limited set of bones shows thickening, leading to localized pain and asymmetry. Other bones remain relatively unaffected, and symptoms may be milder overall. Loved ones may recognize certain types sooner than the person experiencing them.
Skull-predominant
Thickening affects skull bones more than limbs, which can cause headaches, hearing changes, or facial pressure. Limb symptoms may be mild or delayed compared with head symptoms. Doctors sometimes classify symptoms as limb-predominant versus skull-predominant.
Asymptomatic carriers
Some people with the known genetic change have few or no symptoms, discovered only on family testing or imaging. When present, complaints are subtle and may fluctuate over years. The balance of symptoms can shift over time.
What genetics can tell you about symptoms
Certain TGFB1 gene variants in Camurati-Engelmann disease overstimulate bone growth, leading to bone pain, muscle weakness, and fatigue. As bones thicken—especially in the limbs and skull—people may notice limb aches, waddling gait, headaches, hearing loss, or vision changes.
Causes and risk factors
Camurati-Engelmann disease is usually caused by a change in a gene called TGFB1.
It often runs in families in an autosomal dominant pattern, and it can also arise as a new change.
Having a gene change doesn’t mean you’ll definitely develop the condition.
Family history is the main risk, while lifestyle or environment do not cause it but may shape early symptoms of Camurati-Engelmann disease and how strong they feel.
Growth and hormonal shifts can influence when bone changes begin and how active the disease seems.
Environmental and biological risk factors
Camurati-Engelmann disease is a rare bone condition that typically begins early in life. For this condition, the likelihood of it occurring appears to come largely from biology within the body, with few proven links to outside exposures. Two people with the same exposure can react very differently—biology shapes the response. Here’s what is known about environmental and biological elements related to risk.
No specific home, workplace, or community exposures have been shown to raise the chance of Camurati-Engelmann disease. Studies to date have not identified consistent environmental triggers. Because the condition is rare, evidence remains limited.
The chance of new changes arising in sperm increases as fathers get older. This general pattern may slightly raise the likelihood of a new case starting in a family, though data specific to Camurati-Engelmann disease are limited. Exact risk size is not well defined.
Radiation to the reproductive organs (for example, certain cancer treatments) can damage eggs or sperm. While not linked directly to Camurati-Engelmann disease, such exposure can increase the chance of new changes being passed to a child.
High-level exposure to heavy metals or certain solvents can harm reproductive cells. There is no evidence that these exposures specifically raise the risk for this condition. Workplace protections and safety limits keep routine exposures low.
Genetic risk factors
Most cases trace back to a single gene, TGFB1, which when altered makes a growth signal in bone overly active. Some risk factors are inherited through our genes. Camurati-Engelmann disease typically follows an autosomal dominant pattern, but severity can vary widely even within a family. New (de novo) changes can appear in a child with no prior family history.
TGFB1 gene variants: Pathogenic changes in the TGFB1 gene make the TGF-beta1 protein overactive, driving abnormal thickening of long bones. This is the main genetic cause in people with Camurati-Engelmann disease. Different variants can lead to different degrees of activity and symptoms.
Autosomal dominant pattern: One altered copy of TGFB1 is enough to cause the condition. Each child of an affected parent has a 50% chance of inheriting the variant, and sons and daughters are equally likely.
De novo changes: Many people have Camurati-Engelmann disease with no prior family history because the TGFB1 change arose new in the egg, sperm, or early embryo. In these cases, the chance of parents having another affected child is usually low but not zero if mosaicism is present.
Variable severity: People with the same TGFB1 variant can have very different symptoms and ages of onset. Some have only subtle features, while others develop pain, tiredness, or walking limits earlier in life. This variability often reflects how strongly the change affects signaling and the person’s genetic background.
Parental mosaicism: Occasionally, a parent carries the TGFB1 change in only some cells, so standard blood testing can look normal. This mosaicism can slightly increase the chance of another child with Camurati-Engelmann disease after an apparently de novo case.
Family history: Having a biological parent with Camurati-Engelmann disease is a strong genetic risk. The likelihood for each child is 50% if that parent has a confirmed TGFB1 variant. Severity in the parent does not predict severity in the child.
Genetic testing: Genetic testing for Camurati-Engelmann disease typically involves sequencing the TGFB1 gene to confirm the diagnosis. Identifying the family’s variant allows targeted testing of relatives to see who is at risk. Test results also help with planning care and monitoring.
Lifestyle risk factors
Camurati-Engelmann disease is a genetic bone condition; lifestyle habits do not cause it, but they can influence symptoms, day-to-day function, and complications. This overview focuses on how lifestyle affects Camurati-Engelmann disease, especially pain, fatigue, and mobility. In practice, lifestyle risk factors for Camurati-engelmann disease mean choices that can worsen or ease bone pain, muscle fatigue, and gait limits. Tailoring activity, rest, and diet to your symptoms can meaningfully improve comfort and participation in daily life.
Repeated jumping, running, or heavy lifting can trigger or worsen bone pain and limping in Camurati-Engelmann disease. Choosing lower-impact options helps reduce flares while staying active.
Swimming, cycling, or walking on soft surfaces can maintain fitness without overloading painful long bones. Regular, moderate sessions may improve stamina and reduce post-activity pain.
Targeted core, hip, and leg strengthening plus gentle stretching improve muscle support around sclerotic bones. Better conditioning can lessen fatigue and improve walking tolerance.
Long bouts of standing or fast increases in activity can precipitate pain spikes and exhaustion. Breaking tasks into shorter blocks with planned rests can prevent flares.
Risk prevention
Camurati-Engelmann disease is a genetic bone condition, so true prevention of the disease isn’t possible. Prevention focuses on easing flares, protecting mobility, and catching complications early. Prevention is about lowering risk, not eliminating it completely. Knowing early symptoms of Camurati-Engelmann disease can prompt timely care and support.
Learn how the condition is inherited and your chance of passing it on. Discuss options like prenatal testing or IVF with embryo testing if family planning is on your mind.
See specialists who know this condition to monitor bones, nerves, hearing, and vision. Early checks can spot pressure on nerves in the skull, anemia, or movement changes before they cause bigger problems.
Low‑impact strength and flexibility work can support weak muscles and steady your gait. A therapist can set pacing rules so activity helps rather than triggers pain or fatigue.
Use a stepwise plan with approved pain relievers, heat or ice, and rest breaks. Review medicines regularly to avoid side effects and adjust doses during flares.
Transmission
Camurati-Engelmann disease is not contagious; you can’t catch it from someone else, and everyday contact is completely safe. It is usually passed down in a dominant pattern, meaning one changed copy of a gene is enough to cause the condition; if a parent has Camurati-Engelmann disease, each child has a 50% chance of inheriting it. Sometimes Camurati-Engelmann disease appears for the first time in a family because of a new genetic change, so there may be no earlier family history. If you’re wondering about how Camurati-Engelmann disease is inherited, a genetics professional can review your family history and discuss risks for future children.
When to test your genes
Camurati-Engelmann disease is a genetic bone disorder, so consider testing if you have unexplained limb pain, muscle weakness, or a family history of the condition. Genetic confirmation can guide monitoring, pain management, and family planning. Test sooner if symptoms began in childhood or multiple relatives are affected.
Diagnosis
People with Camurati-Engelmann disease often seek answers because of deep, aching bone pain, tired legs, or a waddling walk that makes everyday tasks harder. Getting a diagnosis is often a turning point toward answers and support. In many cases, doctors recognize a pattern on exam and X-rays, then confirm it with a genetic test. Clinicians typically use a stepwise approach to the diagnosis of Camurati-Engelmann disease, moving from clinical features to imaging and finally genetic confirmation.
A clinician looks for bone pain, muscle weakness, a wide-based or waddling gait, and tenderness along the mid-portions of long bones. Height and limb alignment are checked, and a focused neurologic and musculoskeletal exam helps define the pattern.
A detailed family and health history can help identify relatives with similar bone pain or gait changes. Because this condition can run in families, patterns across generations may guide testing.
Standard X-rays often show thickened bone along the shafts of long bones with the ends less affected. This diaphyseal pattern is a key clue for Camurati-Engelmann disease and helps distinguish it from other causes of bone pain.
A nuclear medicine bone scan can show increased uptake along the affected bone shafts. This highlights active bone remodeling and helps map how widespread the changes are.
Stages of Camurati-engelmann disease
Camurati-Engelmann disease does not have defined progression stages. Symptoms and X-ray changes can vary widely between people and over time, so clinicians follow how things change rather than assigning a fixed stage. Early symptoms of Camurati-Engelmann disease often include limb pain, fatigue, and a waddling gait; evaluation usually combines a physical exam with imaging of the long bones and, when appropriate, genetic testing of the TGFB1 gene. Different tests may be suggested to help confirm the diagnosis and to monitor changes, such as X-rays taken over time or, in some cases, MRI or a bone scan.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, and with Camurati-Engelmann disease the answer is shaped by how active the bone changes are and how early care begins. Most people live a normal lifespan. The condition tends to cause periods when symptoms such as deep bone pain, fatigue, and muscle weakness flare, followed by quieter stretches. Doctors call this the prognosis—a medical word for likely outcomes. Early symptoms of Camurati-Engelmann disease often appear in childhood or the teen years, and for many, pain management, tailored exercise, and careful use of medicines help keep day-to-day life on track.
Over time, most people with Camurati-Engelmann disease find their symptoms stabilize or become more predictable with treatment, though some continue to need regular adjustments to their plan. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Severe complications are uncommon, but when bone thickening affects areas like the skull base or nerve openings, headaches, hearing changes, or nerve pain can occur and may need specialist care. The future may look uncertain now, but with monitoring and a coordinated team, many people maintain work, school, and family activities.
Looking at the long-term picture can be helpful. While there may be challenges ahead, most people with Camurati-Engelmann disease do not face life-threatening issues from the condition itself. Pain flares, reduced stamina, and gait changes are the main drivers of impact; these can ebb and flow across the years. Talk with your doctor about what your personal outlook might look like, including how often to check bone changes, when to adjust medications, and what signs should prompt a sooner visit.
Long-term effects
Camurati-Engelmann disease is a lifelong genetic bone condition that can affect comfort, mobility, and stamina over time. Long-term effects vary widely, and they can change from childhood into adulthood. Early symptoms of Camurati-Engelmann disease often appear in childhood and may include bone pain and fatigue that come and go. Most people have a normal life expectancy, though daily life can be shaped by pain levels and how much the skull or long bones are involved.
Progressive thickening of the long bones can cause deep, aching pain. These changes often start in childhood and may slowly extend to other bones. Pain levels can fluctuate over time.
A waddling gait and reduced range of motion can develop. Longer walks or climbing stairs can increase discomfort and tiredness. For some, pace and endurance lessen over years.
Muscles near affected bones can feel weak and tire quickly. This contributes to slower movement and difficulty with running or lifting. It can make everyday tasks feel more effortful.
Thickening of skull bones can lead to headaches and a feeling of pressure. In some, compression around nerves can affect hearing or vision. These features may emerge gradually.
How is it to live with Camurati-engelmann disease?
Living with Camurati-Engelmann disease often means managing deep, aching bone pain and muscle weakness that can flare with activity and ease with rest, shaping choices about work, school, and leisure. Fatigue is common, so pacing, planned breaks, and flexible routines help many stay active without overdoing it. People may notice changes in body shape or a waddling gait, and noise sensitivity or headaches can occur, which can affect social plans; clear communication with family, friends, and coworkers makes support more practical and less guesswork. With a care team, tailored pain control, physical therapy, and accommodations at home or work, many find a steady rhythm that protects energy while preserving independence and connection.
Treatment and drugs
Treatment for Camurati-Engelmann disease focuses on easing pain, improving mobility, and protecting bone and muscle health over time. Supportive care can make a real difference in how you feel day to day, and many people benefit from a mix of medicines, physical therapy, and activity pacing to manage fatigue and muscle weakness. Doctors commonly use pain relievers and anti-inflammatory medicines; some may try corticosteroids for short periods to reduce inflammation, and in selected cases, drugs that affect bone remodeling, such as bisphosphonates, may be considered with close monitoring. Alongside medical treatment, lifestyle choices play a role, including guided exercise to maintain strength and flexibility, assistive devices if needed, and nutrition support to help with weight maintenance. Because Camurati-Engelmann disease varies in severity, your doctor may adjust your dose to balance benefits and side effects and coordinate care with specialists in genetics, orthopedics, pain management, and physiotherapy.
Non-drug treatment
Non-drug care for Camurati-Engelmann disease focuses on easing bone pain, protecting mobility, and managing day-to-day fatigue. Alongside medicines, non-drug therapies can build strength and comfort so you can do more with less flare. Understanding early symptoms of Camurati-Engelmann disease can help tailor these supports sooner and prevent avoidable setbacks.
Gentle strengthening and stretching help support weak muscles and stiff joints. A therapist can pace workouts to reduce pain flares in Camurati-Engelmann disease.
Water reduces joint loading so you can move more freely with less pain. Pool sessions can build endurance and core strength safely.
Breaking tasks into short blocks with planned rests can curb fatigue and soreness. Many living with Camurati-Engelmann disease find energy lasts longer with this rhythm.
Practical tips and ergonomic tools make daily tasks easier. Therapists can teach joint protection and energy-saving strategies at home and work.
Your genes may have an impact on how drugs work for you
Medicines for Camurati‑Engelmann disease can work differently depending on genes that affect inflammation pathways and how the body processes drugs. Genetic testing may help guide dosing or drug choice, aiming for better pain control and fewer side effects.
Pharmacological treatments
Living with Camurati-Engelmann disease often means managing bone pain, fatigue, and mobility limits so daily tasks feel doable again. Medicines aim to reduce pain and inflammation, and in some cases address pathways tied to the condition. Not everyone responds to the same medication in the same way. Your healthcare team may combine options and adjust over time based on benefits and side effects.
Common choices include ibuprofen, naproxen, or diclofenac to ease bone pain and inflammation. They can irritate the stomach or affect the kidneys, so take with food and check dosing limits.
Acetaminophen (paracetamol) can help pain when anti-inflammatories aren’t a fit. Avoid exceeding daily limits to protect the liver and review other products that may also contain it.
Prednisone or prednisolone may reduce pain and improve walking stamina during flares. Doctors aim for the lowest effective dose and gradual taper to limit side effects like weight gain or bone thinning.
Pamidronate (IV), alendronate, or zoledronic acid may lessen pain for some, though results are mixed. Monitoring includes kidney function and calcium levels, and dental checks are often advised.
Genetic influences
Most cases of Camurati-Engelmann disease are linked to changes in a gene called TGFB1, which affects signals that guide bone growth and remodeling. A change in a gene (mutation or variant) can sometimes affect health. Camurati-Engelmann disease is typically inherited in a dominant pattern, so if a parent carries the TGFB1 change, each child has a 1 in 2 (50%) chance of inheriting it. That said, the first person in a family can develop it due to a new, spontaneous gene change, so a family history isn’t always present. Symptoms and how severe they are can vary widely, even among relatives with the same TGFB1 change. Genetic testing for Camurati-Engelmann disease and a visit with a genetic counselor can confirm the cause and help you understand risks for future pregnancies and other family members.
Is Camurati-engelmann disease genetic?
Genetics are central in Camurati-Engelmann disease, which is usually caused by inherited changes in the TGFB1 gene. Most cases follow an autosomal dominant pattern, though new (de novo) variants can occur. Genetic testing confirms the diagnosis and enables family counseling.
Pharmacogenetics—how genetics influence drug effects
In Camurati-Engelmann disease, care often includes pain relievers, anti-inflammatory medicines, and sometimes drugs that calm an overactive TGF‑beta pathway; your genes can affect how well some of these work and the chance of side effects. Some common NSAID pain relievers are cleared by a liver enzyme that varies from person to person, so slower processors may have higher levels and more side effects at usual doses, while faster processors may get less relief. Genetic testing can sometimes identify how your body converts codeine or tramadol, which helps doctors choose a different pain option if needed. Losartan, used by some to target the TGF‑beta pathway in Camurati‑Engelmann disease, depends on liver enzymes to form its most active form, and certain inherited differences can change how much benefit you get. The gene change that causes Camurati‑Engelmann disease (often in TGFB1) points to pathway‑targeting strategies, but it doesn’t by itself predict your reaction to everyday pain medicines. Not all variability is genetic—age, weight, other medications, and liver or kidney health matter too—so clinicians combine your medical history with any relevant pharmacogenetic results to tailor treatment.
Interactions with other conditions
Pain, fatigue, and muscle weakness from Camurati-Engelmann disease can overlap with other conditions like osteoarthritis, fibromyalgia, or neuropathies, so day-to-day it may be hard to tell which issue is driving symptoms. Doctors call it a “comorbidity” when two conditions occur together. Anti-inflammatory medicines or long-term steroids sometimes used for Camurati-Engelmann disease can affect blood sugar, blood pressure, and bone strength, so coexisting diabetes, hypertension, or osteoporosis may need closer monitoring and adjusted dosing. If the skull bones are involved, added pressure around nerves can complicate existing hearing or vision problems, and chronic sinus or ear issues may feel worse during flares. Because early symptoms of Camurati-Engelmann disease can mimic arthritis or overuse injuries, having another pain condition can delay diagnosis and make it harder to sort out what’s causing a bad day. Close coordination among your primary doctor, genetics, orthopedics, neurology, and ENT can align treatments and reduce the chance that one therapy interferes with another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described painful, heavy-feeling limbs that started in youth and seemed to run in families. In some households, a child who loved to run began to tire quickly, while a parent remembered having the same deep, aching legs as a teenager. These community stories often pointed to what we now recognize as Camurati-Engelmann disease.
First described in the medical literature as progressive thickening of the long bones with limb pain and fatigue, the condition was initially understood only through symptoms, X‑rays, and family patterns. In the early 1900s, radiographs revealed a striking picture: the outer layers of certain bones looked unusually dense and widened, especially in the arms and legs. Doctors noted that the changes often appeared in childhood or adolescence and could vary widely—even within the same family.
Over time, descriptions became more precise. Clinicians learned to distinguish Camurati-Engelmann disease from other causes of bone pain and overgrowth, such as metabolic bone disorders or chronic infections. Reports from different countries outlined a shared core pattern—limb pain, easy fatigue, and thickening of the diaphyses (the shafts) of long bones—alongside variability in severity, flares, and age at onset. Not every early description was complete, yet together they built the foundation of today’s knowledge.
Advances in genetics transformed understanding in the late 20th and early 21st centuries. Researchers linked Camurati-Engelmann disease to changes in a gene that helps regulate bone growth signals, explaining why bone can lay down too much hard tissue along the shafts. This finding clarified why the condition often appears across generations and why symptoms can be so different from one person to another. DNA research now explains family patterns that clinicians had observed for decades.
With this genetic insight, historical case series were reinterpreted. Some individuals once thought to have unusual or “atypical” forms actually fit well within the spectrum of Camurati-Engelmann disease. The genetic marker also guided more consistent diagnosis, especially when early symptoms of Camurati-Engelmann disease—such as limb pain, weakness, or tiredness—preceded obvious changes on imaging.
Today’s picture blends careful historical observation with modern tools. Earlier recognition allows families to understand inheritance, plan follow-up, and manage symptoms more effectively. Knowing the condition’s history highlights how far care has come—from pattern spotting on early X‑rays to targeted genetic testing—and underscores a key lesson from the past: Camurati-Engelmann disease is variable, and support should be tailored to each person’s experience.